Introduction
============

The predictive value of NGAL for renal recovery is not established.

Methods
=======

Data from the first 19 patients were assessed during a multicentre low molecular weight heparin trial (FBI, EudraCT Number: 2012-004368-23). Critically ill patients with AKI are randomly assigned into either a treatment arm (1 mg/kg enoxaparin) or a control arm (40 mg enoxaparin) upon commencement of CRRT. The primary outcome is the occurrence of venous thromboembolism. NGAL was measured at baseline and during CRRT-free intervals.

Results
=======

Patients were comparable at baseline with respects to demographics, APACHE II, creatinine, NGAL, start of dialysis, and the duration of dialysis. The main cause of AKI was sepsis (42%). In 63% of the patients, the reason for starting dialysis was a combination of anuria and electrolyte disturbances. Twenty-six percent of patients were dialysis dependent after the first CRRT-free interval. Plasma NGAL levels were higher in nonrenal recovery patients (1,074 (±694) ng/ml) compared with renal recovery patients (296 (±197) ng/ml; *P*= 0.01). Urine NGAL levels were higher in nonrenal recovery patients (3,885 (±2,722) ng/ml) compared with renal recovery patients (597 (±565) ng/ ml; *P*= 0.006). See Figures [1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}. Inflammatory parameters (WBCs, CRP, and procalcitonin) did not differ significantly between the groups.
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Conclusion
==========

NGAL may be able to predict renal recovery, and allow proper utilization of resources.
